“Shingles Market” report has been added to DelveInsight
Shingles Overview
Shingles, also known as herpes zoster (HZ), is a viral infection caused by the chickenpox virus, varicella-zoster virus (VZV). Herpes zoster results from activation of the virus, which in many instances has remained latent for years following a primary chickenpox infection. Once active, the virus travels along a nerve to the skin and causes a rash.
Shingles Market:Forecast
DelveInsight’s “Shingles – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Shingles, historical and forecasted epidemiology as well as the Shingles market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Request free sample copy @ https://www.delveinsight.com/sample-request/shingles-market
Shingles Market: By Regions Covered
Shingles Key Players
Shingles Drugs
Shingles Symptoms
Early symptoms of shingles may include fever and general weakness. During the 2 or 3 days before shingles development, most people have pain, a tingling sensation, or itching in a strip of skin (a dermatome) on one side of the body. Clusters of small, fluid-filled blisters surrounded by a small red area then develop on the strip of skin. Typically, the blisters occur only on the limited area of skin supplied by the infected nerve fibers. They are most common on the torso and face, but they can occur elsewhere as well. In rare cases, the rash appears on the lower body. Though, Shingles may develop at any age but is most common after age 50. The chance of developing shingles increases as people age.
Shingles Diagnosis
The signs and symptoms of herpes zoster are usually distinctive enough to make an accurate clinical diagnosis once the rash has appeared. If characteristic blisters appear in the typical pattern (on a strip of skin representing a dermatome), the diagnosis is clear. However, diagnosis of herpes zoster might not be possible in the absence of a rash (i.e., before rash or in cases of zoster without rash). Laboratory testing may be useful in cases with less typical clinical presentations, such as in people with suppressed immune systems who may have disseminated herpes zoster.
Shingles Market:Research
During chickenpox, the virus spreads in the bloodstream and infects collections of nerve cells (ganglia) of the spinal or cranial nerves. The virus remains in the ganglia in an inactive (dormant or latent) state. The virus may never cause symptoms again, or it may reactivate many years later. When it reactivates, the virus travels down the nerve fibers to the skin, where it creates painful sores resembling those of chickenpox. This outbreak of sores (shingles) almost always appears on a strip of the skin over the infected nerve fibers and only on one side of the body. This strip of skin, the area supplied by nerve fibers from a single spinal nerve region, is called a dermatome. Sores may also appear on the dermatomes or next to the affected dermatome.
Shingles Treatment
Shingrix vaccine has been approved by the US FDA to prevent shingles and is recommended for adults aged 50 years and older. Other than this vaccine, Shingles treatments include several antiviral drugs such as famciclovir or valacyclovir. These drugs do not cure the disease, but they can help relieve shingles symptoms and shorten their duration. Pain–reliving drugs, anti-inflammation drugs, narcotic medications and others are also prescribed for treatment of the symptoms.
Shingles Market: Report Highlights
Shingles Treatment Market
Treatment for Shingles must be initiated by a dermatologist or other health-care provider within 3 days of getting the rash. Ideally, if the treatment is initiated within 3 days, it can prevent possible complications, such as long-lasting nerve pain. However, receiving treatment after 3 days still has benefits.
Shingles Market Insights
Shingrix is a new shingles vaccine developed by GlaxoSmithKline and was approved by the US FDA in 2017. It contains inactivated varicella-zoster viral particles, which aids the body’s production of more antibodies that are necessary to fight the virus with a stronger immune system response. As an inactive vaccine, it may be administered to patients with compromised immune systems. It reduces the risk of getting shingles by more than 90% and it’s effective for five years.
Shingles Emerging Key Players
There are a few emerging key players, which are expected to enter the Shingles market in the coming years, which includes Nobelpharma (Fostoin), Curevo (CRV-101) and NanoViricides (NV-HHV-101). These therapies are under early phase clinical development and the launch of these therapies is expected during the forecast period of 2021–2030.
Table of content
1. Key Insights
2. Executive Summary of Shingles
3. Competitive Intelligence Analysis for Shingles
4. Shingles: Market Overview at a Glance
5. Shingles: Disease Background and Overview
6. Patient Journey
7. Shingles Epidemiology and Patient Population
9. Unmet Needs
10. Key Endpoints of Shingles Treatment
11. Marketed Products
12. Emerging Therapies
13. Shingles: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Shingles
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Shingles Market Report Key Strengths
Why should you buy this report?
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/